Ogkologos

4396 ΔΗΜΟΣΙΕΥΣΕΙΣ 0 ΣΧΟΛΙΑ

A “Living Medicine:” Engineered E. coli Shrink Tumors in Mice

Ogkologos - 11 Δεκεμβρίου, 2024

EMA Recommends Extension of Indications for Pembrolizumab to Malignant Pleural Mesothelioma

Ogkologos - 11 Δεκεμβρίου, 2024

FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a...

Ogkologos - 10 Δεκεμβρίου, 2024

Nivolumab plus Ipilimumab Improves PFS Over Chemotherapy Among Previously Untreated Patients...

Ogkologos - 9 Δεκεμβρίου, 2024

Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with...

Ogkologos - 6 Δεκεμβρίου, 2024

Treatment Strategy for ecDNA-Driven Tumors Shows Potential

Ogkologos - 5 Δεκεμβρίου, 2024

Combining Radiotherapy with SOC Plus Abiraterone Improves rPFS in Patients with...

Ogkologos - 5 Δεκεμβρίου, 2024

EMA Recommends Granting a Marketing Authorisation for Lazertinib

Ogkologos - 4 Δεκεμβρίου, 2024

FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-Cell...

Ogkologos - 3 Δεκεμβρίου, 2024

ESMO Immuno-Oncology Congress 2024, Geneva, Switzerland, 11-13 December

Ogkologos - 2 Δεκεμβρίου, 2024

1...626364...440 Σελίδα 63 από 440

MOST POPULAR

El cáncer en mi comunidad: Ampliar el acceso a las pruebas...

1 Σεπτεμβρίου, 2020

Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients...

10 Σεπτεμβρίου, 2025

Aggressive Prostate Cancer Subtype More Common Than Expected

31 Ιουλίου, 2018

High Response Rates Observed Following KTE-X19 CAR T-Cell Therapy in Adults...

15 Ιουνίου, 2021

Φόρτωση περισσοτέρων

A “Living Medicine:” Engineered E. coli Shrink Tumors in Mice

EMA Recommends Extension of Indications for Pembrolizumab to Malignant Pleural Mesothelioma

FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a...

Nivolumab plus Ipilimumab Improves PFS Over Chemotherapy Among Previously Untreated Patients...

Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with...

Treatment Strategy for ecDNA-Driven Tumors Shows Potential

Combining Radiotherapy with SOC Plus Abiraterone Improves rPFS in Patients with...

EMA Recommends Granting a Marketing Authorisation for Lazertinib

FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-Cell...

ESMO Immuno-Oncology Congress 2024, Geneva, Switzerland, 11-13 December

MOST POPULAR

El cáncer en mi comunidad: Ampliar el acceso a las pruebas...

Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients...

Aggressive Prostate Cancer Subtype More Common Than Expected

High Response Rates Observed Following KTE-X19 CAR T-Cell Therapy in Adults...

HOT NEWS

Countdown to 100,000 OncoLife Survivorship Care Plans: What is a Survivorship...

Oncology Dietitians Don’t Usually Inquire About Food Insecurity in Cancer Patients,...

Alex Trebek Thanks Fans In “Mind-Boggling” Cancer Update.

Patients with Advanced Hodgkin’s Lymphoma Treated with Brentuximab Vedotin Plus AVD...

ΔΗΜΟΦΙΛΕΊΣ ΘΈΣΕΙΣ

ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ)

ΣΤΑΤΙΣΤΙΚΑ

ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ

ΔΗΜΟΦΙΛΗ ΚΑΤΗΓΟΡΙΑ